对外授权收入锐减,康方生物由盈转亏,明星抗癌药依沃西进入医保有望放量

时代周报
31 Mar

因由BD(商务拓展)交易带来的盈利未能持续,康方生物(09926.HK)再次转亏。图片来源:图虫创意3月30日晚间,康方生物披露2024年财务报告。财报显示,2024年,康方生物收入为21.24亿元,同比下降53.08%;录得扣除分销成本后的商业销售收入总额为20.02亿元,同比增长24.88%;录得毛利18.35亿元,同比下降58.23%;年内亏损5.01亿元,较2022年亏损大幅缩窄。2023...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10